- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05800015
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irrespective of PD-L1 Expression Levels
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who have advanced non-small cell lung cancer (NSCLC).
The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is for treating advanced NSCLC, in comparison with cemiplimab and chemotherapy.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drugs
- How much of each study drug is in your blood at different times
- Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)
- How administering the study drugs might improve your quality of life
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Study Locations
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2109
- Recruiting
- Macquarie University Health Science Center (MQ Health)
-
Contact:
- John Park
- Email: john.park@mqhealth.org.au
-
Wollongong, New South Wales, Australia, NSW 2500
- Recruiting
- Southern Medical Day Care Centre
-
Contact:
- Daniel Paul Brungs
-
-
Victoria
-
Ballarat, Victoria, Australia, 3350
- Recruiting
- Ballarat Regional Integrated Cancer Centre (BRICC)
-
Contact:
- Wasek Faisal
- Email: wasek.faisal@bhs.org.au
-
Bendigo, Victoria, Australia, 3550
- Recruiting
- Bendigo Hospital
-
Contact:
- Say Ng
- Email: sng@bendigohealth.org.au
-
Fitzroy, Victoria, Australia, 3065
- Recruiting
- St Vincents Hospital
-
Contact:
- Melissa Moore
- Email: melissa.moore@svha.org.au
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Recruiting
- St John of God Murdoch Hospital
-
Contact:
- Kynan Feeney
- Email: kynan@oncowest.com.au
-
-
-
-
-
Tbilisi, Georgia, 0114
- Recruiting
- Ltd New Hospitals
-
Contact:
- Davit Giorgadze
- Email: d.giorgadze@onco.ge
-
Tbilisi, Georgia, 0112
- Recruiting
- Israeli Georgian medical research clinic Helsicore
-
Contact:
- Ekaterine Arkania
- Email: arkadiaek@yahoo.com
-
Tbilisi, Georgia, 0159
- Recruiting
- JSC K. Eristavi National Center of Experimental and Clinical Surgery
-
Contact:
- Mamia Khutashvilli
- Email: mamology@yahoo.com
-
Tbilisi, Georgia, 0159
- Recruiting
- LTD Archangel St. Michael Multiprofile Clinical Hospital
-
Contact:
- Nia Shavdia
- Email: shavdiania@yahoo.com
-
Tbilisi, Georgia, 0160
- Recruiting
- TIM- Tbilisi Intitute of Medicine
-
Contact:
- Mariam Zhvania
- Email: m.zhvania@onco.ge
-
Tbilisi, Georgia, 112
- Recruiting
- Research Institute of Clinical Medicine
-
Contact:
- Tamar Melkadze
- Email: tmelkadze@hotmail.com
-
Tbilisi, Georgia, 144
- Recruiting
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Contact:
- Miranda Gogishvilli
- Email: mirandagogishvili@yahoo.com
-
Tbilisi, Georgia, 179
- Recruiting
- JSC Evex Hospitals - Caraps Medline
-
Contact:
- Nana Chikhladze
- Email: nanuka.chikhladze@yahoo.com
-
Tbilisi, Georgia, 159
- Recruiting
- The Institute of Clinical Oncology
-
Contact:
- Vladimer Kuchava
- Email: ladokuchava@gmail.com
-
-
Adjaria
-
Batumi, Adjaria, Georgia, 6000
- Recruiting
- LTD Cancer Center of Adjara
-
Contact:
- Tamta Makharadze
- Email: tamta.makharadze@gmail.com
-
-
-
-
-
Daejeon, Korea, Republic of, 35015
- Recruiting
- Chungnam National University Hospital
-
Contact:
- Hyewon Ryu
-
Incheon, Korea, Republic of, 21565
- Recruiting
- Gachon University Gil Medical Center
-
Contact:
- Hee Kyung Ahn
-
Incheon, Korea, Republic of, 22332
- Recruiting
- Inha University Hospital
-
Contact:
- Jeong Seon Ryu
-
Seoul, Korea, Republic of, 8308
- Recruiting
- Korea University Guro Hospital
-
Contact:
- Sung Yong Lee
- Email: syl0801@korea.ac.kr
-
Ulsan, Korea, Republic of, 44033
- Recruiting
- Ulsan University Hospital
-
Contact:
- Young Joo Min
- Email: yjmin65@gmail.com
-
-
Chungbuk
-
Cheongju-si, Chungbuk, Korea, Republic of, 28644
- Recruiting
- Chungbuk National University Hospital
-
Contact:
- Ki Hyeong Lee
- Email: kihlee1963@gmail.com
-
-
Gyeonggi
-
Suwon, Gyeonggi, Korea, Republic of, 16499
- Recruiting
- Ajou University Hospital
-
Contact:
- Hyun Woo Lee
-
-
Gyeonggi Do
-
Seongnam-si, Gyeonggi Do, Korea, Republic of, 13520
- Recruiting
- CHA Bundang Medical Center, CHA University
-
Contact:
- Joo-Hang Kim
- Email: kim123@cha.ac.kr
-
-
Jeollabuk-do
-
Jeonju, Jeollabuk-do, Korea, Republic of, 54907
- Recruiting
- Jeonbuk National University Hospital
-
Contact:
- Eun-Kee Song
- Email: eksong@jbnu.ac.kr
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center
-
Contact:
- Sang-We Kim
- Email: swkim@amc.seoul.kr
-
-
-
-
Arizona
-
Yuma, Arizona, United States, 85364
- Recruiting
- Yuma Regional Medical Center
-
Contact:
- Abhinav Chandra, MD
- Email: abchandra@yumaregional.org
-
-
California
-
Cerritos, California, United States, 90703
- Recruiting
- Innovative Clinical Research Institute
-
Contact:
- Arati Chand
- Email: achand@airesearch.us
-
Orange, California, United States, 92868
- Recruiting
- St. Joseph Hospital Orange
-
Contact:
- Timothy Byun, MD
- Email: timothy.byun@stjoe.org
-
Rancho Mirage, California, United States, 92270
- Recruiting
- Desert Hematology Oncology Medical Group, Inc.
-
Contact:
- Luke Dreisbach
-
Redlands, California, United States, 92373
- Recruiting
- Emad Ibrahim, MD, Inc.
-
Contact:
- Emad Ibrahim, MD
-
Whittier, California, United States, 90602
- Recruiting
- PIH Health Hospital
-
Contact:
- Jeremy Chuang
- Email: Jeremy.Chuang@pihhealth.org
-
-
Florida
-
Clermont, Florida, United States, 34711
- Recruiting
- Clermont Oncology Center
-
Contact:
- Gopal Kunta, MD
- Email: drgkunta@aorcorp.com
-
Miami, Florida, United States, 33125
- Recruiting
- Miami Veterans Administration HealthCare Systen
-
Contact:
- Niramol Savaraj, MD
- Email: nsavaraj@med.miami.edu
-
Orange City, Florida, United States, 32763
- Recruiting
- Mid Florida Hematology and Oncology Center
-
Contact:
- Santosh Nair
-
Tallahassee, Florida, United States, 32308
- Recruiting
- Tallahassee Memorial HealthCare
-
Contact:
- Karen Russell, MD
- Email: karen.russell@tmh.org
-
-
Illinois
-
Rolling Meadows, Illinois, United States, 60008
- Recruiting
- Northwest Oncology and Hematology
-
Contact:
- Bruce Bank
- Email: bruceb@northwestoncology.com
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Recruiting
- Mary Bird Perkins Cancer Center
-
Contact:
- Victor Lin, MD
- Email: vlin@marybird.com
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Recruiting
- Hattisburg Clinic
-
Contact:
- John Hrom
- Email: bo.hrom@hattiesburgclinic.com
-
-
New Jersey
-
Pennington, New Jersey, United States, 08534
- Recruiting
- Capital Health Hopewell Medical Center
-
Contact:
- Arturo Loaiza-Bonilla, MD
- Email: aloaiza-bonilla@capitalhealth.org
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Recruiting
- New Mexico Cancer Care Alliance
-
Contact:
- Atul Kumar, MD
- Email: AtKumar@salud.unm.edu
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai
-
Contact:
- Thomas Marron, MD
- Email: thomas.marron@mountsinai.org
-
Westbury, New York, United States, 11590
- Recruiting
- Clinical Research Alliance Inc.
-
Contact:
- James D'Olimpio
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center Research
-
Contact:
- Gabrail Nashat, MD
- Email: research@gabrailcancercenter.com
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Recruiting
- West Cancer Center
-
Contact:
- Jason Porter, MD
- Email: jporter@westclinic.com
-
Knoxville, Tennessee, United States, 37920
- Recruiting
- University of Tennessee Medical Center
-
Contact:
- Neil Faulkner, MD
- Email: NFaulkner@utmck.edu
-
Knoxville, Tennessee, United States, 37916-2300
- Recruiting
- Thompson Cancer Survival Center (TCSC) Downtown
-
Contact:
- David Chism
- Email: dchism.research@covhlth.com
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- University of Virginia Medical Center
-
Contact:
- Richard Hall
- Email: rdh3q@virginia.edu
-
Midlothian, Virginia, United States, 23114
- Recruiting
- Bon Secours Cancer Institute Richmond
-
Contact:
- William Irvin
- Email: william_irvin@bshsi.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Patients with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic disease), who received no prior systemic treatment for recurrent or metastatic NSCLC.
- Availability of an archival or on-study formalin-fixed, paraffin-embedded (FFPE) tumor tissue sample, without intervening therapy between biopsy collection and screening as described in the protocol
- For enrollment in phase 2, patients should have PD-L1, expression results (regardless of expression level) determined by a College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) (or equivalently licensed, according to local regulations) accredited laboratory, as described in the protocol. For enrollment in phase 3, patients should have a valid PD-L1 result, regardless of expression level, using an assay as performed by a central laboratory, as described in the protocol.
- At least 1 radiographically measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
- Adequate organ and bone marrow function as defined in the protocol.
Key Exclusion Criteria:
- Active or untreated brain metastases or spinal cord compression. Patients are eligible if central nervous system (CNS) metastases are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. Patients must be off (immunosuppressive doses of) corticosteroid therapy.
- Patients with tumors tested positive for actionable estimated glomerular filtration rate (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene translocations, or ROS oncogene 1 (ROS1) fusions, as described in the protocol.
- Encephalitis, meningitis, or uncontrolled seizures in the year prior to enrollment.
- History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment.
- Known primary immunodeficiencies, either cellular (eg, DiGeorge syndrome, T-cell-negative severe combined immunodeficiency [SCID]) or combined T- and B-cell immunodeficiencies (eg, T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
- Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk of immune-mediated treatment-emergent adverse events (imTEAEs). Patients with uncontrolled type 1 diabetes mellitus or with uncontrolled adrenal insufficiency are excluded. The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that required only hormone replacement, or psoriasis that does not require systemic treatment.
- Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomization. Physiologic replacement doses are allowed even if they are >10 mg of prednisone/day or equivalent, as long as they are not being administered for immunosuppressive intent. Patients with clinically relevant systemic immune suppression within the last 3 months before trial enrollment are excluded. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder.
Patients who have received prior systemic therapies are excluded with the exception of the following:
- Adjuvant or neoadjuvant platinum-based doublet chemotherapy (after surgery and/or radiation therapy) if recurrent or metastatic disease develops more than 6 months after completing therapy as long as toxicities have resolved to CTCAE grade ≤1 or baseline with the exception of alopecia and peripheral neuropathy.
- Anti-PD-(L)1 with or without LAG-3 as an adjuvant or neoadjuvant therapy as long as the last dose is >12 months prior to enrollment.
- Prior exposure to other immunomodulatory or vaccine as an adjuvant or neoadjuvant therapy such as Cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibodies as long as the last dose is >6 months prior to enrollment. Immune-mediated AEs must be resolved to CTCAE grade ≤1 or baseline by the time of enrollment. Endocrine immune-mediated AEs controlled with hormonal or other non-immunosuppressive therapies without resolution prior to enrollment are allowed.
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 2 - Arm A
Randomized 1:1:1 fianlimab (higher dose) + cemiplimab + platinum-doublet chemotherapy
|
Administered intravenously (IV) every 3 weeks (Q3W)
Other Names:
Administered IV Q3W
Other Names:
IV Infusion, Q3W
Other Names:
IV Infusion, Q3W
IV Infusion, Q3W
Other Names:
IV infusion, Q3W
Other Names:
|
Experimental: Phase 2 - Arm B
Randomized 1:1:1 fianlimab (lower dose) + cemiplimab + platinum-doublet chemotherapy
|
Administered intravenously (IV) every 3 weeks (Q3W)
Other Names:
Administered IV Q3W
Other Names:
IV Infusion, Q3W
Other Names:
IV Infusion, Q3W
IV Infusion, Q3W
Other Names:
IV infusion, Q3W
Other Names:
|
Experimental: Phase 2 - Arm C
Randomized 1:1:1 cemiplimab + platinum-doublet chemotherapy + placebo
|
Administered IV Q3W
Other Names:
IV Infusion, Q3W
Other Names:
IV Infusion, Q3W
IV Infusion, Q3W
Other Names:
IV infusion, Q3W
Other Names:
IV infusion, Q3W
|
Experimental: Phase 3 - Arm A or B
Randomized 1:1 fianlimab (chosen dose) + cemiplimab + platinum-doublet chemotherapy
|
Administered intravenously (IV) every 3 weeks (Q3W)
Other Names:
Administered IV Q3W
Other Names:
IV Infusion, Q3W
Other Names:
IV Infusion, Q3W
IV Infusion, Q3W
Other Names:
IV infusion, Q3W
Other Names:
|
Experimental: Phase 3 - Arm C
Randomized 1:1 cemiplimab + platinum-doublet chemotherapy + placebo
|
Administered IV Q3W
Other Names:
IV Infusion, Q3W
Other Names:
IV Infusion, Q3W
IV Infusion, Q3W
Other Names:
IV infusion, Q3W
Other Names:
IV infusion, Q3W
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) as assessed by blinded independent review committee (BICR) using RECIST 1.1
Time Frame: Up to 136 Weeks
|
Phase 2 ORR is defined as proportion of patients with a best overall response of confirmed complete response (CR) or partial response (PR).
|
Up to 136 Weeks
|
Overall Survival (OS)
Time Frame: Up to 5 years
|
Phase 3 Defined as the time from randomization to the date of death due to any cause
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse event (TEAEs)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 A TEAE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment
|
Up to 108 weeks
|
Incidence of treatment-related TEAEs
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Incidence of serious adverse events (SAEs)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 Any untoward medical occurrence that at any dose:
|
Up to 108 weeks
|
Incidence of adverse events of special interest (AESIs)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 Serious or non-serious; is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate.
Such an event might warrant further investigation in order to characterize and understand it.
|
Up to 108 weeks
|
Incidence of immune-mediated adverse events (imAEs)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 Immune-mediated AEs are thought to be caused by unrestrained cellular immune responses directed at normal host tissues.
An imAE can occur shortly after the first dose or several months after the last dose of treatment.
Early detection and management reduces the risk of severe drug induced toxicity
|
Up to 108 weeks
|
Occurrence of interruption of study drug(s) due to AEs
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Occurrence of discontinuation of study drug(s) due to AEs
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Incidence of deaths due to TEAE
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Incidence of grade 3-4 laboratory abnormalities
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 ≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0] |
Up to 108 weeks
|
ORR by investigator assessment using RECIST 1.1
Time Frame: Up to 136 Weeks
|
Phase 2 & Phase 3
|
Up to 136 Weeks
|
Disease control rate (DCR) by BICR
Time Frame: Up to 136 Weeks
|
Phase 2 and Phase 3 DCR is defined as CR + PR + stable disease (SD)
|
Up to 136 Weeks
|
DCR by investigator assessment
Time Frame: Up to 136 Weeks
|
Phase 2 and Phase 3 DCR is defined as CR + PR + stable disease (SD)
|
Up to 136 Weeks
|
Time to tumor response (TTR) by BICR
Time Frame: Up to 136 Weeks
|
Phase 2 and Phase 3 TTR is defined as the time from randomization to the date of the first response of CR or PR (whichever is first recorded) for patients with confirmed CR or PR.
|
Up to 136 Weeks
|
TTR by investigator assessment
Time Frame: Up to 136 Weeks
|
Phase 2 and Phase 3 TTR is defined as the time from randomization to the date of the first response of CR or PR (whichever is first recorded) for patients with confirmed CR or PR
|
Up to 136 Weeks
|
Duration of response (DOR) by BICR
Time Frame: Up to 5 Years
|
Phase 2 and Phase 3 DOR is defined as the time from first response of CR or PR to first radiographic progression or death due to any cause for patients with confirmed CR or PR
|
Up to 5 Years
|
DOR by investigator assessment
Time Frame: Up to 5 Years
|
Phase 2 and Phase 3 DOR is defined as the time from first response of CR or PR to first radiographic progression or death due to any cause for patients with confirmed CR or PR
|
Up to 5 Years
|
Progression free survival (PFS) by BICR
Time Frame: Up to 5 Years
|
Phase 2 and Phase 3 PFS is defined as the time from randomization to the date of the first radiographic progression or death due to any cause, whichever occurred earlier
|
Up to 5 Years
|
PFS by investigator assessment
Time Frame: Up to 5 Years
|
Phase 2 and Phase 3 PFS is defined as the time from randomization to the date of the first radiographic progression or death due to any cause, whichever occurred earlier
|
Up to 5 Years
|
OS
Time Frame: Up to 5 Years
|
Phase 2 Defined as the time from randomization to the date of death due to any cause
|
Up to 5 Years
|
Change from baseline in physical functioning per EORTC QLQ-C30
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Change from baseline in patient-reported chest pain per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 EORTC QLQ-LC 13 is a lung cancer specific module developed to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients
|
Up to 108 weeks
|
Change from baseline in patient-reported dyspnea per EORTC QLQ-LC13
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Change from baseline in patient-reported cough per EORTC QLQ-LC13
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Time until definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Time until definitive deterioration in patient-reported physical functioning per EORTC QLQ-C30
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Time until definitive deterioration in patient-reported chest pain per EORTC QLQ-LC13
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Time until definitive deterioration in patient-reported dyspnea per EORTC QLQ-LC13
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Time until definitive deterioration in patient-reported cough per EORTC QLQ-LC13
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Time until definitive deterioration in a composite of these three symptoms: patient-reported chest pain, dyspnea and cough per EORTC QLQ-LC13
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Change from baseline in patient-reported general health status per EuroQoL 5-Dimensional 5-Level Scale (EQ-5D-5L) VAS
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 The EQ-5D-5L VAS records the respondent's self-rated health on a 10 centimeter (cm) vertical, visual analogue scale.
It is rated by the respondent on a scale 0 to 100, with 0 being "the worst health you can imagine" and 100 being "the best health you can imagine".
|
Up to 108 weeks
|
Change from baseline in patient-reported severity with usual or daily activities due to fatigue per the Patient Reported Outcomes for Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 PRO-CTCAE questionnaire assesses side effect symptoms in cancer clinical trials using a PRO-CTCAE score.
The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.
|
Up to 108 weeks
|
Change from baseline in patient-reported interference with usual or daily activities due to fatigue per the PRO-CTCAE
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3
|
Up to 108 weeks
|
Concentrations of cemiplimab in serum
Time Frame: Up to 136 weeks
|
Phase 2 & Phase 3
|
Up to 136 weeks
|
Concentrations of fianlimab in serum
Time Frame: Up to 136 weeks
|
Phase 2 & Phase 3
|
Up to 136 weeks
|
Immunogenicity, as measured by anti-drug antibodies (ADA) to fianlimab
Time Frame: Up to 136 weeks
|
Phase 2 & Phase 3
|
Up to 136 weeks
|
Immunogenicity, as measured by ADA to cemiplimab
Time Frame: Up to 136 weeks
|
Phase 2 & Phase 3
|
Up to 136 weeks
|
Immunogenicity, as measured by neutralizing antibodies (NAb) to fianlimab
Time Frame: Up to 136 weeks
|
Phase 2 & Phase 3
|
Up to 136 weeks
|
Immunogenicity, as measured by NAb to cemiplimab
Time Frame: Up to 136 weeks
|
Phase 2 & Phase 3
|
Up to 136 weeks
|
Change from baseline in patient-reported global health status/quality of life (GHS/QoL) per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Time Frame: Up to 108 weeks
|
Phase 2 & Phase 3 EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a GHS/QoL scale.
Participants rate items on a four-point scale, with 1 as "not at all" and 4 as "very much."
A change of 5 - 10 points is considered a small change.
A change of 10 - 20 points is considered a moderate change.
|
Up to 108 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Folic Acid Antagonists
- Carboplatin
- Paclitaxel
- Pemetrexed
- Cemiplimab
Other Study ID Numbers
- R3767-ONC-2236
- 2022-501577-40-00 (Registry Identifier: EUCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on fianlimab
-
Regeneron PharmaceuticalsNot yet recruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Regeneron PharmaceuticalsNot yet recruitingColorectal CancerUnited States
-
Regeneron PharmaceuticalsNot yet recruiting
-
Regeneron PharmaceuticalsSanofiRecruitingHepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Regeneron PharmaceuticalsSanofiActive, not recruitingMalignanciesUnited States, Korea, Republic of, Australia, Ireland, United Kingdom
-
Regeneron PharmaceuticalsRecruitingAdvanced Non-Small Cell Lung CancerKorea, Republic of, United States, Australia, Georgia
-
Regeneron PharmaceuticalsNot yet recruiting
-
Regeneron PharmaceuticalsRecruitingMelanomaUnited States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
-
Regeneron PharmaceuticalsRecruitingMelanomaUnited States, Australia, Spain, United Kingdom, Canada, Brazil, Mexico, Germany, Ireland, South Africa, France, Israel, Georgia, Turkey, Italy, Poland, Chile, Argentina, Belgium, Czechia, Romania, Greece
-
Regeneron PharmaceuticalsNot yet recruiting